Pancreatic Cancer Market

Market Overview:

The 7 major pancreatic cancer markets reached a value of US$ 2,114.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8,005.8 Million by 2034, exhibiting a growth rate (CAGR) of 12.86% during 2024-2034.

The pancreatic cancer market has been comprehensively analyzed in IMARC's new report titled "Pancreatic Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pancreas is a gland located in the abdomen that produces enzymes to aid digestion and hormones for regulating blood sugar. Pancreatic cancer is a disease that develops when abnormal cells in the pancreas begin to grow and divide uncontrollably, forming a mass or tumor. This cancer can interfere with the normal functioning of the pancreas, and if left untreated, it can spread to other parts of the body. Some common symptoms of the ailment are abdominal or back pain, unintentional weight loss, jaundice (yellowing of the skin and eyes), and changes in bowel movements. Other signs may include nausea, vomiting, and loss of appetite. Diagnosing pancreatic cancer typically involves a combination of imaging tests, such as CT scans, MRI scans, ultrasound, etc., as well as blood tests to check for elevated levels of certain proteins and enzymes. A biopsy may also be performed to confirm the presence of cancerous cells.

The rising prevalence of chronic pancreatitis and diabetes, which cause changes in the cells of the pancreas and increase the risk of disease development, is primarily driving the pancreatic cancer market. In addition to this, the widespread adoption of non-invasive ways to monitor treatment response and detect cancer recurrence, such as liquid biopsy which utilizes patient's blood to identify cancer-specific biomarkers, is also creating a positive outlook for the market. Moreover, the emerging popularity of the Whipple procedure as a surgical treatment option for patients whose pancreatic cancer is localized and has not spread to other organs is further augmenting the market growth. Apart from this, the rising utilization of combination therapies, including multiple types of chemotherapy, targeted therapy, and immunotherapy, on account of improving patient outcomes and survival rates, is acting as a significant growth-inducing factor. Furthermore, the escalating adoption of minimally invasive surgical procedures, such as laparoscopic and robotic-assisted surgeries, owing to their several associated benefits, including shorter hospital stays and faster recovery times, is also propelling the market. Besides this, recent technological advancements in genetic biomarker discovery, such as next-generation sequencing (NGS), gene expression profiling (microarray), polymerase chain reaction (PCR), and proteomics, are expected to drive the pancreatic cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pancreatic cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pancreatic cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pancreatic cancer market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the pancreatic cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the pancreatic cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pancreatic cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the pancreatic cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the pancreatic cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the pancreatic cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of pancreatic cancer across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pancreatic cancer by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pancreatic cancer by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pancreatic cancer by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with pancreatic cancer across the seven major markets?
• What is the size of the pancreatic cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of pancreatic cancer?
• What will be the growth rate of patients across the seven major markets?
   

Pancreatic Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for pancreatic cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pancreatic cancer market?
• What are the key regulatory events related to the pancreatic cancer market?
• What is the structure of clinical trial landscape by status related to the pancreatic cancer market?
• What is the structure of clinical trial landscape by phase related to the pancreatic cancer market?
• What is the structure of clinical trial landscape by route of administration related to the pancreatic cancer market?